Tivicay (dolutegravir) / ViiV Healthcare 
Welcome,         Profile    Billing    Logout  
 26 Diseases   58 Trials   58 Trials   4692 News 


«12345678910111213...6263»
  • ||||||||||  Review, Journal:  Two-Drug Combination Antiretroviral Therapy for HIV-1: Case Series and Literature Review. (Pubmed Central) -  Nov 17, 2024   
    Two-drug cART including DOR appears to be an acceptable option for patients who may be limited to alternative ART regimens due to drug-drug interactions, resistance mutations, or toxicities. Additional evidence from case reports or clinical trials are needed to further evaluate the long-term efficacy and safety of DOR as part of a two-drug cART regimen.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Review, Journal:  Children who are HIV exposed-uninfected: does maternal ART regimen matter? (Pubmed Central) -  Nov 15, 2024   
    Dolutegravir continues to appear safe in pregnancy. Randomized trials of specific regimens during pregnancy and breastfeeding, including long-acting and newer ART drugs with long-term follow-up of children, are critical to understand the contribution of ART exposure to CHEU outcomes.
  • ||||||||||  Preclinical, Journal:  Bictegravir alters glucose tolerance in vivo and causes hepatic mitochondrial dysfunction. (Pubmed Central) -  Nov 13, 2024   
    This study evaluated the impact of lamivudine, dolutegravir (DTG), bictegravir (BIC), tenofovir disoproxil fumarate, and TAF on metabolic alterations, and explored glucose homeostasis and mitochondrial stress as potential mechanisms...BIC promoted mitochondrial dysfunction, modified carbohydrate metabolism and glucose consumption in hepatocytes, and altered glucose tolerance and gluconeogenesis regulation in mice. These findings suggest that BIC contributes to insulin resistance and diabetes in people living with HIV, warranting clinical studies to clarify its association with carbohydrate metabolism disorders.
  • ||||||||||  Dovato (dolutegravir/lamivudine) / ViiV Healthcare, lamivudine / Generic mfg., Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Efficacy and safety of 2-drug regime dolutegravir/lamivudine in pregnancy and breastfeeding (Pubmed Central) -  Nov 13, 2024   
    Although 3DR remains the preferred therapy during pregnancy and breastfeeding, this case indicates that DTG/3TC may be an effective alternative for patients experiencing intolerance or poor adherence to 3DR. Further studies are needed to explore the impact of pharmacokinetic changes in pregnancy on 2DR efficacy and to confirm its safety and role in preventing MTCT.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
    Journal:  Paediatric antiretroviral therapy challenges with emerging integrase resistance. (Pubmed Central) -  Nov 13, 2024   
    However, children remain disadvantaged when DTG-based first-line ART fails or cannot be used. Research efforts to address this inequity require prioritisation in order to ensure health outcomes are optimised for all ages in all settings.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Enrollment open:  REDOCH: Selection of Resistant Mutations to Dolutegravir in PLWH Treated in Mozambique (clinicaltrials.gov) -  Nov 12, 2024   
    P=N/A,  N=200, Recruiting, 
    Research efforts to address this inequity require prioritisation in order to ensure health outcomes are optimised for all ages in all settings. Not yet recruiting --> Recruiting
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal:  Factors linked to virological failure in people on a dolutegravir-based regimen in Mamelodi. (Pubmed Central) -  Nov 7, 2024   
    Since 2019, the World Health Organization has recommended dolutegravir-containing regimens for HIV in low- and middle-income countries because of its high genetic barriers to resistance, lower drug interactions, fewer side effects, higher viral load (VL) suppression rates and cost-effectiveness compared to efavirenz...The study highlights the importance of addressing adherence factors to improve VL suppression rates among people living with HIV on TLD. Tailored interventions targeting adherence, especially among newly initiated patients, and addressing the use of traditional or herbal and religious products are warranted to enhance treatment outcomes.
  • ||||||||||  Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare
    Biomarker, Journal:  Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study. (Pubmed Central) -  Nov 3, 2024   
    A relevant proportion of neurologically asymptomatic participants had abnormal CSF and serum NFL levels during primary HIV infection. NFL and GFAP decreased in serum following combination antiretroviral therapy without significant differences among the treatment arms.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Journal, Viral vector:  Update on Managing the Risks of Exposure to Lentiviral and Retroviral Vectors. (Pubmed Central) -  Oct 29, 2024   
    The DTG-based ART is a highly cost-effective strategy compared with the EFV-based ART among women initiating treatment in the third trimester of pregnancy in a low-income setting. Because of the highly efficient delivery of transgenes by modern lentiviral and retroviral vectors, postexposure prophylaxis is indicated to prevent vector integration and oncogenic risks.
  • ||||||||||  Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
    Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment?na () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_532;    
    P3
    Because of the highly efficient delivery of transgenes by modern lentiviral and retroviral vectors, postexposure prophylaxis is indicated to prevent vector integration and oncogenic risks. Introduction: The ALLIANCE study showed that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was non-inferior to dolutegravir + emtricitabine/tenofovir disoproxil fumarate at achieving HIV-1 RNA suppression, and superior at achieving HBV DNA suppression at week 48 in treatment-na
  • ||||||||||  Isentress (raltegravir) / Merck (MSD)
    Mortality using raltegravir versus other integrase inhibitors in people with HIV in Europe and Australia () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_489;    
    Introduction: The ALLIANCE study showed that bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was non-inferior to dolutegravir + emtricitabine/tenofovir disoproxil fumarate at achieving HIV-1 RNA suppression, and superior at achieving HBV DNA suppression at week 48 in treatment-na A prior study among ART-na
  • ||||||||||  bictegravir (GS-9883) / Gilead, Tivicay (dolutegravir) / ViiV Healthcare
    Economic estimation of the management of neuropsychiatric events in people with HIV in real life (Virtual) -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_413;    
    Real-world discontinuation rates due to NPAEs with BIC are lower than with DTG, leading to savings in cost and resource use for their management. Findings from this study could help treatment decision-making in PHIV.
  • ||||||||||  Tivicay (dolutegravir) / ViiV Healthcare
    Assessing the effects of age and polypharmacy on dolutegravir exposure in plasma and the central nervous system () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_370;    
    Overall, further exploring DTG pharmacodynamics in the CNS and associations with NP-AEs will be pivotal in assessing the impact of low DTG CNS concentrations on long-term HIV management. P225: Figure 1Open in figure viewerPowerPoint Simulated results of DTG administered 50 mg once daily for 14 consecutive days in plasma (a) and CSF (b).
  • ||||||||||  Women living with HIV: how far to fulfil the gap? () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_307;    
    Moreover, they were characterized by higher burden of comorbidities, in particular obesity and diabetes. That led to multiple vicious circles, enhanced by different cultural, social and economic determinants: treatment choice of 3DR versus dual regimen, difficulties in screening and management of comorbidities, lower rate of cancer screening.
  • ||||||||||  Sunlenca (lenacapavir) / Gilead
    Early treatment failure with lenacapavir in HIV?2 infection () -  Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_273;    
    The found integrase mutations are most probably associated with resistance and were leading to subsequent LEN mono therapy. Further studies are needed to investigate the effectiveness and the use of LEN in salvage settings in HIV-2 patients.